Chairman Michael J. Farrell - 15 Jul 2022 Form 4 Insider Report for RESMED INC (RMD)

Role
Chief Executive Officer
Signature
Michael J. Farrell, Chief Executive Officer
Issuer symbol
RMD
Transactions as of
15 Jul 2022
Net transactions value
-$948,729
Form type
4
Filing time
18 Jul 2022, 13:31:24 UTC
Previous filing
05 Jul 2022
Next filing
17 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RMD ResMed Common Stock Options Exercise $327,788 +5,675 +1.4% $57.76 410,935 15 Jul 2022 Direct F1
transaction RMD ResMed Common Stock Sale $1,276,517 -5,675 -1.4% $224.94 405,260 15 Jul 2022 Direct F1, F2
holding RMD ResMed Common Stock 3,880 15 Jul 2022 Lisette and Michael Farrell Foundation
holding RMD ResMed Common Stock 5,090 15 Jul 2022 Lisette and Michael Farrell Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RMD ResMed Common Stock Options Options Exercise $0 -5,675 -5.7% $0.000000 94,265 15 Jul 2022 ResMed Common Stock 5,675 $57.76 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction was conducted under a Rule 10b5-1 plan.
F2 This transaction was executed in multiple trades at prices ranging from $222.45 to $225.95. The price reported above reflects the weighted average sale price.
F3 Represents date options first became exercisable. Options vest 1/3 per year.